• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
3 E Network Technology Group Ltd - Class A Ordinary Shares
Adidas Ag
Akouos, Inc. - Common Stock
Aterian, Inc. - Common Stock
Avalon Advanced Materials Inc
Avicanna Inc
Avis Budget Group, Inc. - Common Stock
Barclays Plc
BlackRock Municipal Income Fund, Inc. Common Stock
Brookmount Expls Inc
Callan JMB Inc. - Common Stock
Dividend Growth Split Corp
DoorDash, Inc. - Common Stock
FAT Brands Inc. - Class B Common Stock
Faraday Future Intelligent Electric Inc. - Warrant
First High-School Education Group ADR
First Trust New Opportunities MLP & Energy Fund Common Shares of Beneficial Inte
FirstEnergy Corp
Gas Utilities Sector
Goldhills Hldg Ltd
Healthy Extracts Inc
Hemogenyx Pharmaceuticals Plc.
Immuron Limited - American Depositary Shares
Invesco MSCI Global Timber ETF
LQR House Inc. - Common Stock
Metacrine, Inc. - Common Stock
Opiant Pharmaceuticals, Inc. - Common Stock
PLAYSTUDIOS, Inc. - Warrant
PayPal Holdings, Inc. - Common Stock
Power & Digital Infrastructure Acquisition Corp. - Class A Common Stock
Premium Catering (Holdings) Limited - Ordinary Shares
Purple Innovation, Inc. - Common Stock
Rakuten Group Inc
SAI.TECH Global Corporation - Class A Ordinary Shares
SAIHEAT Limited - Class A Ordinary Shares
SeaChange International, Inc. - Common Stock
Shanghai
Snap-On
Snow Lake Resources Ltd. - Common Shares
SunScout Holding Limited Class A Ordinary Shares
Tidewater Renewables Ltd
Tivity Health, Inc. - Common Stock
Triad Business Bank
University Bancorp Inc
Verve Therapeutics, Inc. - Common Stock
Village Farms International, Inc. - Common Shares
Vor Biopharma Inc. - Common Stock
YieldMax Short COIN Option Income Strategy ETF
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Satellos Bioscience Inc.

< Previous 1 2 Next >
News headline image
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
February 24, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
February 18, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos to Participate in Upcoming Investor Conferences
February 17, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
February 12, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 10, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
February 09, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
February 06, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers TSX:MSCL
News headline image
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
February 05, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
January 29, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
January 28, 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
December 09, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in December Investor Conferences
November 25, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
November 18, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
November 14, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in November Investor Conferences
October 30, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
October 21, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
October 10, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
September 29, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
September 22, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in Four September Institutional and Retail Investor Conferences
August 21, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
August 13, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
August 05, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
July 16, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Shareholders Elect Two New Board Members
June 18, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
June 18, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
June 16, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
May 22, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
May 13, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at the CureDuchenne FUTURES National Conference
May 07, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
April 29, 2025
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap